Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.65 USD
Change Today -0.21 / -2.37%
Volume 2.0M
ACHN On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 4:00 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

achillion pharmaceuticals (ACHN) Key Developments

Achillion Pharmaceuticals, Inc. Announces Resignation of Dennis Liotta as Class I Director

Dennis Liotta, a Class I director of Achillion Pharmaceuticals, Inc. resigned from the company’s Board of Directors.

Achillion Pharmaceuticals Inc. Enters into Worldwide License and Collaboration Arrangement with Janssen Pharmaceuticals

Achillion Pharmaceuticals Inc. (ACHN) has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals Inc., to develop and commercialize one or more of Achillion's lead hepatitis C virus assets which include ACH-3102, ACH-3422, and Sovaprevir. The collaboration focuses on the development of a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of hepatitis C virus, or HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in phase 2 clinical studies in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration. Achillion is eligible to receive about $1.1 billion in potential development, regulatory and sales milestone payments under the collaboration. Additionally, Johnson & Johnson Innovation - JJDC, Inc. will invest $225 million in Achillion and, in return, receive about 18.4 million newly issued, unregistered shares of Achillion at a price of $12.25 per share. Derma Sciences Inc. (DSCI) is aiming to complete enrollment in its phase III program with Aclerastide in subjects with diabetic foot ulcers by the end of June 2016.

Achillion Pharmaceuticals Enters into Worldwide License and Collaboration Arrangement with Janssen Pharmaceuticals, Inc

Achillion Pharmaceuticals entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, Inc. to develop and commercialize one or more of Achillion's lead hepatitis C virus (HCV) assets which include ACH-3102, ACH-3422, and sovaprevir. Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets. A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in Phase 2 clinical studies that has been granted Fast Track designation by the U.S. Food and Drug Administration, in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration.

Achillion Pharmaceuticals, Inc. - Special Call

To discuss worldwide license and collaboration arrangement with Janssen Pharmaceuticals, Inc. to develop and commercialize one or more of the company's lead hepatitis C virus (HCV) assets which include ACH-3102, ACH-3422, and sovaprevir

Achillion Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Achillion Pharmaceuticals, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $19,399,000, net loss of $19,263,000 or $0.17 loss per share against loss from operations of $16,235,000, net loss of $16,088,000 or $0.17 loss per for the same period a year ago. Interest income for the first quarter ended March 31, 2015 was $152,000 compared to $158,000 for the same quarter ended March 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACHN:US $8.65 USD -0.21

ACHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACHN.
View Industry Companies
 

Industry Analysis

ACHN

Industry Average

Valuation ACHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACHILLION PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.